NanoViricides Inc., a publicly traded company focused on developing broad-spectrum antivirals, has announced that the design of its adaptive clinical trial protocol for treating MPox Virus Clade Ia and Ib infections with the novel drug NV-387 is nearing completion. The trial aims to gather data on safe and effective dosing regimens, the safety and tolerability of the drug, and its antiviral effectiveness. The adaptive, randomized, standard of care controlled trial will enroll approximately 80 patients and proceed in two parts. In the Phase IIa part, NV-387 will be compared with the standard of care over an initial six-day dosing period, with potential for extension based on patient outcomes. Currently, no drug is approved as effective for treating MPox. If NV-387 proves effective, it would be the first drug to demonstrate effectiveness against an orthopoxvirus in human clinical trials. Results of the trial are expected to provide crucial insights into the drug's safety and efficacy.